articleJournal of Clinical OncologyApr 22, 2022HYBRID OA

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

RSRoy S. HerbstMMMargarita MajemFBFabrice BarlesiECEnric CarcerenyQCQuincy Chu

Yale Cancer Center · Hospital de Sant Pau · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE Durvalumab significantly improves overall survival for patients with unresectable stage III non–small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. METHODS Patients with unresectable stage III non–small-cell lung cancer, Eastern Cooperative Oncology Group performance status 0/1, and no progression after cCRT were randomly assigned 1:1:1, ≤ 42 days post-cCRT, to durvalumab alone or combined with oleclumab or monalizumab for up to 12 months,…

Citation impact

278
total citations
FWCI
27.98
Percentile
100%
References
19
Citations per year

Authors

16
  • RS
    Roy S. HerbstCorresponding

    Yale Cancer Center

  • MM
    Margarita Majem

    Hospital de Sant Pau

  • FB
    Fabrice Barlesi

    Institut Gustave Roussy

  • EC
    Enric Carcereny

    Institut Català d'Oncologia

  • QC
    Quincy Chu

Topics & keywords

Topics
Keywords
  • Durvalumab
  • Lung cancer
  • Phases of clinical research
  • Stage (stratigraphy)
  • Cancer
  • Multiple drug resistance
  • Chemotherapy
No related works found for this paper.

Funding